about
Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosisSinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD.Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib.Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities.Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement.The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study.Treatment of Spontaneous Bacterial Peritonitis.Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis.Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma.Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas.Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease.Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window.Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome.Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction.Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis.Harmful and Beneficial Effects of Anti-coagulants in Patients With Cirrhosis and Portal Vein Thrombosis.Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis.Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction.Therapy of the refractory ascites: Total paracentesis vs. TIPS.Reply to the diagnostic conundrum of bacterial infections in cirrhotic patients.Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase.HCV infection, HOMA index and sustained virological response: the step we need to take before moving forward.Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areasVon Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertensionDiagnosis of thrombophilia/prothrombotic conditions in patients with liver disease.Insulin resistance and liver microcirculation in a rat model of early NAFLDAntibiotic prophylaxis during bleeding for portal hypertensionProphylaxis of rebleeding in hepatocellular carcinoma: pushing the envelope or a real clinical benefit?Bacterial translocation and nonselective β-blockers in portal hypertension: where we are, what we still needMultimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendationsCoagulation, Microenvironment and Liver FibrosisMetabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosisEvaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver diseaseRenin-angiotensin-aldosterone system in cirrhosis: There's room to try!
P50
Q26774531-5A79EF59-11A3-4363-B6E1-6A6971F88F46Q34234946-15D5FFC9-C8FD-49B0-8B0D-0AD158661B22Q35095916-85447EDB-5178-40CC-AF0F-9B1F446E8AFAQ37045749-C85B5DBB-64C3-48B5-8B37-B4B055438EB8Q37122348-154291EA-CBE6-442E-9BF4-B31F9572F17DQ38417924-C7BA9E3F-0502-470B-A0A7-99BBD500BA14Q40629864-A2896309-DDB3-471D-B162-F8E7DB8046E3Q41116135-C06A25B4-6C11-45CE-82D4-967AF44EE0E2Q41411573-39A11D68-B915-4DCF-8092-8C488651E233Q41669686-13A6E9C8-C39C-4875-A628-E1CE1F53FCA8Q42980538-607D6147-585F-47DF-860A-27B1EB9BC0DEQ43036848-91CFB3E4-9935-4B3C-85F9-E453546CCE6BQ43040750-450A5099-C5C5-4F6F-8567-FC7EB9470750Q43165730-3690DBF8-D00B-4C64-9B2A-85A542F14AB3Q44633511-A34CE6DA-C56F-4256-AB1B-7AA213084F0FQ44743116-24D78291-67C1-4E75-ACD4-4AD0134F87E8Q45873489-2F106280-B9E2-48C0-BB06-C556460A2E9EQ45873561-E1229057-8138-4E37-9F3C-B0801A2A6E7CQ45883014-7567CB90-92A0-45A8-B15A-DF7F9ADD61DDQ45980095-1894B5A7-BDA8-4459-9398-7DE1ABB27FA3Q46517321-340C9371-C620-4410-A0DA-B529BA360D8AQ47903461-A26608F5-0874-46B0-B26B-94511B45CFB6Q48169566-9C02533B-F463-42C1-ACA9-3AFE4128CBC3Q49841498-81441A22-2E70-4D77-9077-1CA3C1DC13F4Q50452803-672773E2-5441-42EC-87AC-9C4ABF6A46D8Q50553124-225D791B-DE0E-4477-9924-730426FE561AQ50576256-18146AA6-6AF4-4CB5-8B29-88E96CDD717AQ51803900-D78FA6BA-37C3-40C4-8330-2473EBA5AF67Q56958259-5A67D98C-E9B2-44C7-AC1F-AA57746D60E9Q59288270-91972CA0-A63E-47B5-A0AB-9FD6B034D6C4Q64985390-AF9671E8-8153-43BC-A87E-995F319B43D4Q83486914-6BCEE726-48B3-4413-B4FE-3AD28A9F26AAQ84966932-B8738C40-65B5-4C4F-9C38-6E014B558E85Q85346344-39FE92AD-7FC0-4CF7-92D6-13BF29682DE2Q87964794-CC473B6A-56D9-4430-AA93-0F9184E9C8D9Q88786167-A761BA0C-9860-4A03-8110-D368ED5C89F4Q90452318-1236123B-88CA-49AB-A6C0-ACF76901527BQ91023635-233869FB-6893-423C-BF3D-DFC66E942751Q91256875-6DF4D0E0-57BD-4D3F-B024-9103FD9DA37CQ91471863-B30030B8-B4FB-452D-BE80-B94C26E9BCBF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vincenzo La Mura
@ast
Vincenzo La Mura
@en
Vincenzo La Mura
@es
Vincenzo La Mura
@nl
type
label
Vincenzo La Mura
@ast
Vincenzo La Mura
@en
Vincenzo La Mura
@es
Vincenzo La Mura
@nl
prefLabel
Vincenzo La Mura
@ast
Vincenzo La Mura
@en
Vincenzo La Mura
@es
Vincenzo La Mura
@nl
P106
P1153
23008586600
P21
P31
P496
0000-0003-4685-7184